Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ainos, Inc. - warrants
(NQ:
AIMDW
)
0.0495
UNCHANGED
Streaming Delayed Price
Updated: 9:30 AM EDT, Oct 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0495
Bid (Size)
0.0309 (7)
Ask (Size)
0.0594 (12)
Prev. Close
0.0495
Today's Range
0.0495 - 0.0495
52wk Range
0.0250 - 0.5730
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
October 07, 2024
Via
ACCESSWIRE
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
September 25, 2024
Via
ACCESSWIRE
Performance
YTD
-72.25%
-72.25%
1 Month
+98.00%
+98.00%
3 Month
-29.29%
-29.29%
6 Month
+22.22%
+22.22%
1 Year
-89.90%
-89.90%
More News
Read More
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
September 24, 2024
Via
ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
September 23, 2024
Via
ACCESSWIRE
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
September 20, 2024
Via
ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
September 17, 2024
Via
ACCESSWIRE
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Via
ACCESSWIRE
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
August 26, 2024
Via
ACCESSWIRE
Ainos Reports Second Quarter 2024 Financial Results
August 05, 2024
Via
ACCESSWIRE
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
September 03, 2024
Via
ACCESSWIRE
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
August 19, 2024
Via
ACCESSWIRE
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
August 12, 2024
Via
ACCESSWIRE
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
August 09, 2024
Via
ACCESSWIRE
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
June 13, 2024
Via
ACCESSWIRE
Ainos Reports First Quarter 2024 Financial Results
May 13, 2024
Via
ACCESSWIRE
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
May 07, 2024
Via
ACCESSWIRE
Ainos Reports Full Year 2023 Financial Results
March 08, 2024
Via
ACCESSWIRE
Ainos Announces $1.75 Million Follow-On Funding
January 24, 2024
Via
ACCESSWIRE
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 28, 2023
Via
ACCESSWIRE
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 05, 2024
Via
ACCESSWIRE
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
February 01, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 02, 2024
Via
ACCESSWIRE
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 26, 2023
Via
ACCESSWIRE
Ainos, Inc. Announces Stock Consolidation
December 12, 2023
Via
ACCESSWIRE
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 21, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.